Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Feb;21(2):224-8.

Survival impact of autoantibodies in systemic lupus erythematosus

P S Gulko  1 , J D Reveille, W J Koopman, S L Burgard, A A Bartolucci, G S Alarcón
Affiliations
  • PMID: 8182629

Survival impact of autoantibodies in systemic lupus erythematosus

P S Gulko et al. J Rheumatol. 1994 Feb.

Abstract

Objective: To determine the frequency, the clinical and laboratory associations, and the impact on survival of anti-dsDNA, anti-Sm, anti-nRNP, anti-Ro, and anti-La in patients with systemic lupus erythematosus (SLE).

Methods: The clinical and laboratory features of 94 patients with SLE tested for anti-dsDNA, anti-nRNP, anti-Sm, anti-Ro and anti-La were studied. Survival analyses were performed by the Kaplan Meier method.

Results: Anti-Ro, anti-nRNP and anti-Sm were found with lower frequency in our patients compared to other reports. There was a higher frequency of anti-Sm (19.5 vs 10%, p = 0.0093) and anti-nRNP positivity (29.2 vs 7.5%, p = 0.006) among African American patients compared to Caucasian patients. No clinical or laboratory associations were found with any of the autoantibodies. Patients had a mean followup up 11.8 years. There were no protective or negative effects of the different autoantibodies on the probability of survival of the patients studied.

Conclusion: Our study failed to demonstrate the impact of the autoantibodies studied in the survival of our patients.

PubMed Disclaimer

Publication types

LinkOut - more resources